Read by QxMD icon Read


shared collection
2 papers 0 to 25 followers
David Oscier, Claire Dearden, Efrem Eren, Efrem Erem, Christopher Fegan, George Follows, Peter Hillmen, Tim Illidge, Estella Matutes, Don W Milligan, Andrew Pettitt, Anna Schuh, Jennifer Wimperis
No abstract text is available yet for this article.
December 2012: British Journal of Haematology
Valentin Goede, Kirsten Fischer, Raymonde Busch, Anja Engelke, Barbara Eichhorst, Clemens M Wendtner, Tatiana Chagorova, Javier de la Serna, Marie-Sarah Dilhuydy, Thomas Illmer, Stephen Opat, Carolyn J Owen, Olga Samoylova, Karl-Anton Kreuzer, Stephan Stilgenbauer, Hartmut Döhner, Anton W Langerak, Matthias Ritgen, Michael Kneba, Elina Asikanius, Kathryn Humphrey, Michael Wenger, Michael Hallek
BACKGROUND: The monoclonal anti-CD20 antibody rituximab, combined with chemotherapeutic agents, has been shown to prolong overall survival in physically fit patients with previously untreated chronic lymphocytic leukemia (CLL) but not in those with coexisting conditions. We investigated the benefit of the type 2, glycoengineered antibody obinutuzumab (also known as GA101) as compared with that of rituximab, each combined with chlorambucil, in patients with previously untreated CLL and coexisting conditions...
March 20, 2014: New England Journal of Medicine
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"